Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DUPONT MERCK NEUROLITE IMAGING AGENT FOR SPECT STROKE DIAGNOSIS APPROVED

This article was originally published in The Gray Sheet

Executive Summary

DUPONT MERCK NEUROLITE IMAGING AGENT FOR SPECT STROKE DIAGNOSIS APPROVED Nov. 29 by FDA. The Neurolite (technetium 99m bicisate injection) kit is indicated for use in single-photon emission computed tomography (SPECT) as an adjunct to conventional computed tomography (CT) or magnetic resonance imaging (MRI) "in the location of stroke in patients in whom stroke has already been diagnosed," FDA's approval letter states. The drug "is not indicated for assessment of functional viability of brain tissue or for distinguishing between stroke and other brain lesions," the letter adds.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel